Seaside’s Scientific Approach
Autism and other neurodevelopmental disorders have complex and varying etiologies, and the barrier to finding effective treatments has been a lack of basic understanding of the molecular mechanisms underlying these disorders. Seaside Therapeutics is changing the landscape of drug development by focusing on single-gene disorders with a high prevalence of autism, such as fragile X syndrome. Our research first identifies specific molecular pathways affected by a single-gene mutation and then translates this knowledge into novel therapeutics targeting the associated pathway. We then explore utility of these targeted therapeutics for treatment of autism and other neurodevelopmental disorders. Seaside Therapeutics is currently focused on the mGluR5 and GABA-B pathways for the treatment of fragile X syndrome and autism. We have additional ongoing research programs in other single-gene neurodevelopmental disorders such as Rett syndrome and tuberous sclerosis complex.